Abstract: White-coat and masked hypertension are important hypertension phenotypes. Out-of-office blood pressure measurement is essential for the accurate diagnosis and monitoring of these conditions. This review summarizes literature related to the detection and diagnosis, prevalence, epidemiology, prognosis, and treatment of whitecoat and masked hypertension. Cardiovascular risk in white-coat hypertension appears to be dependent on the presence of coexisting risk factors, whereas patients with masked hypertension are at increased risk of target organ damage and cardiovascular events. There is an unmet need for robust data to support recommendations around the use of antihypertensive treatment for the management of white-coat and masked hypertension. (Circ
T he availability of out-of-office blood pressure (BP) measurement, including ambulatory BP monitoring (ABPM) and home BP monitoring (HBPM) has facilitated the identification of different hypertension subtypes and improved the ability to predict cardiovascular risk. This article summarizes evidence relating to white-coat hypertension (WCH) and masked hypertension (MH; Figure 1 ). Articles were identified by searching PubMed using the following terms: (white coat hypertension [ 
White-Coat Hypertension
WCH, also known as isolated clinic hypertension, is a term used to describe elevated clinic or office BP and normal out-of-office BP (on ABPM or HBPM) in individuals not receiving antihypertensive therapy. The corresponding term in treated patients is white-coat effect. First reported in 1988, 1 WCH has been extensively studied over the past 30 years. However, data are not always consistent, often because of imprecise and varying definitions, and there is still no consensus on the prognostic role of WCH or the optimal approach to its management in clinical practice.
Definition and Diagnosis
Accurate diagnosis of WCH is important to avoid the costs and potential side effects associated with unnecessary antihypertensive pharmacotherapy. The last guidelines from the American College of Cardiology (ACC) and American Heart Association (AHA) define WCH as an office BP ≥130/80 mm Hg but <160/100 mm Hg and a daytime BP on ABPM or HBPM of <130/80 mm Hg. 2 In contrast, European guidelines use office BP cutoff values of ≥140 and ≥90 mm Hg. 3 Current guideline cutoff values for the diagnosis of WCH are summarized in Table 1 . In the majority of existing studies, the cutoff values used are ≥140/90 mm Hg for office BP and <135/85 mm Hg for out-of-office BP.
Guidelines recommend the use of out-of-office BP monitoring (ie, ABPM and/or HBPM) to facilitate the diagnosis of hypertension, including detection of WCH. The European position paper on ABPM suggests that individuals with suspected WCH should have the diagnosis confirmed within 3 to 6 months after office BP measurement and have ABPM or HBPM repeated at annual intervals to detect progression to sustained hypertension. 9 In contrast, the Canadian diagnostic algorithm recommends performing HBPM or ABPM after the first visit so that patients with WCH can be identified early in the diagnostic process. 10 It is also suggested that use of automated office BP measurement might reduce the white-coat effect and decrease the number of individuals requiring follow-up with out-of-office BP measurement. 10, 11 One approach to targeting assessment of out-of-office BP is to evaluate characteristics of the change in repeated BP measurements over one clinic visit, which were shown to predict clinical differences between clinic and home BP values. 12 This would allow out-of-office techniques to be recommended for patients deemed more likely to have WCH. HBPM has high specificity but low sensitivity for the diagnosis of WCH, which suggests that it may be most useful for
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facilitating the diagnosis of WCH when used in conjunction with, rather than instead of, ABPM. 13 Another technique to target or reduce use of out-of-office BP monitoring could be use of a deep breathing test. In a clinical trial, subjects who showed a ≥15% decrease in systolic BP (SBP) after 30 seconds of deep breathing were less likely to have WCH diagnosed using ABPM. 14 Nevertheless, evaluation with ABPM or HBPM in the setting of elevated office BP appears to be cost-effective. 15, 16 An important contributor to this was a reduction in medication costs because of treatment based on office BP alone. A model based on data from the Ohasama study estimated medical costs savings of $US 1.56 million per 1000 patients over 5 years when HBPM was incorporated into the diagnosis of hypertension. 17 A different analysis of the same data indicated that widespread implementation of HBPM could reduce hypertension-related medical costs in Japan by $US 9.3 million. 18 
Prevalence, Predictors, and Epidemiology
The first reported prevalence of WCH in patients with diastolic hypertension on conventional measurement was 21%. 1 More recent data from the ARTEMIS (Ambulatory Blood Pressure Registry Telemonitoring of Hypertension and Cardiovascular Risk) project in patients referred for hypertension showed a similar WCH prevalence (23% overall). 19 Other recent reports of WCH prevalence are remarkably consistent, with a rate of 24% based on Spanish ABPM registry data, 20 although lower rates have been reported in Italy population and cohort studies (9%-16%), 21, 22 a meta-analysis of data from Africa (14.8%), 23 and a community-based survey from Taiwan (12%). 24 In the IDACO (International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes), including random population samples from Asia, Europe, and South America, the prevalence of WCH in untreated individuals was 9% overall and 30% in patients with conventional hypertension. 25 Regional differences were noted in the ARTEMIS data, with WCH being less common in Africa, Australia, and America. 19 Also in ARTEMIS, WCH was more common in the elderly and in obese females. 19 This is consistent with other reports that WCH occurs more frequently in women, and older adults, as well as in nonsmokers, and patients with newly diagnosed hypertension who have a limited number of office BP measurements, pregnant women, those with smaller left ventricular (LV) mass, and individuals who do not currently show target organ damage. 9, 26, 27 Other comorbidities shown to be more common in patients with WCH versus normotensive individuals include history of cardiovascular events, higher body mass index (BMI), and higher levels of total cholesterol, serum triglycerides, and serum glucose. 21, 28 It is important to note that the prevalence of WCH is highly dependent on the definition used. For example, using different definitions for WCH in the same population resulted in prevalence rates that ranged from 12.1% to 53.2%. 29 Therefore, the prevalence rate findings from different studies need to be considered taking into account the definition of WCH used, and widespread use of the same definition would facilitate valid between-study comparisons.
30

Effect on Prognosis
The relation between WCH and target organ damage and cardiovascular risk is debated. The most common current view is that the cardiovascular risk associated with WCH is minimal, 31, 32 although increased risk for organ damage and cardiovascular morbidity and mortality has been reported (see below). However, use of imprecise diagnostic criteria may result in misrepresentation of the true nature of WCH, which appears to be relatively benign when there are no other coexisting risk factors.
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values have been shown to be a few units (mm Hg) higher in those with WCH compared with normotensives. 28 Ten-year follow-up data from an Italian longitudinal population study showed that the risk of developing sustained hypertension was significantly higher in participants with WCH (diagnosed using ABPM and HBPM) compared with normotensive individuals after adjustment for sex and age (odds ratio [OR], 2.51; P<0.0001). 33 In a Finnish population-based study, the proportion of patients with WCH based on HBPM who progressed to sustained hypertension over 11 years of follow-up was 52% (compared with 18% for normotensive subjects; multivariable-adjusted relative risk, 2.8; 95% CI, 2.2-3.6; P<0.0001). 34 Data from the Ohasama study, which used HBPM, also suggest that patients with untreated WCH are at increased risk of progressing to sustained hypertension after adjustment for confounding variables.
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Target Organ Damage
One potential mechanism for the target organ effects associated with WCH is an increase in sympathetic activity, which has been documented in WCH. 36, 37 Subclinical organ damage includes LV hypertrophy, carotid atherosclerosis, microalbuminuria, and retinopathy. These cardiac abnormalities and extracardiac target organ damage are important predictors of morbidity and mortality [38] [39] [40] and are therefore important in risk stratification. 3 In general, target organ damage appears to be intermediate for patients with WCH (ie, lower than in sustained hypertension but higher than in normotension), 21, 41, 42 although this is dependent on how WCH was assessed. The intermediate risk of target organ damage in WCH was documented in a meta-analysis of data from 25 ABPM-based studies (including 1705 patients with WCH, 3184 with sustained hypertension, and 2493 without hypertension). 43 Significantly increased LV mass index and pulse wave velocity, and significantly decreased flow-mediated dilation have been documented in untreated patients with newly diagnosed WCH (office BP ≥140/90 mm Hg and 24-hour BP ≤130/80 mm Hg on ABPM; n=204) versus normotensive controls (n=183). 44 In another population-based analysis (n=303), central pulse pressure, aortic pulse wave velocity, carotid intimamedia thickness (IMT), and LV mass index were all higher in those with WCH (based on the 2014 European Society of Hypertension [ESH] practice guidelines for ABPM) 45 compared with normotensive individuals, and differences persisted after adjustment for confounding factors (including 24-hour BP). 46 Another finding in patients with WCH is increased left atrial structural functions and volumes compared with normotensives, suggesting early cardiac remodeling in the presence of WCH, although the number of subjects in this study was small (37 with WCH and 30 healthy individuals). 47 Meta-analysis including 10 published studies (total of 2752 untreated subjects) showed that IMT in the common carotid artery increased progressively from normotension (718±36 μm) through WCH (763±47 μm) to sustained hypertension (817±47 μm). 48 However, only the difference in IMT between normotension and WCH remained statistically significant after adjustment for publication bias. 48 In a cross-sectional survey of a general population from Japan, WCH was significantly associated with carotid atherosclerosis after adjustment for other cardiovascular risk factors (OR, 2.36; 95% CI, 1.27-4.54). 49 The results of a study conducted in a consecutive series of community-dwelling adults showed that common carotid artery IMT was significantly increased in subjects with elevated clinic SBP and normal home BP compared to those with elevated diastolic BP or SBP/diastolic BP in the clinic and normal home BP; IMT values in the elevated clinic SBP group were similar to those in patients with hypertension. 50 This suggests that the nature of clinic BP elevation may play a role in the occurrence of target organ damage in WCH. In addition, the risk of target organ damage in patients with WCH has been shown to be related not only to BP characteristics but also to the presence of concomitant metabolic abnormalities. 51 Data from a cross-sectional survey of community-dwelling Japanese subjects aged ≥40 years showed a significant increase in the presence of albuminuria in those with WCH compared with normotensives, after adjustment for age and sex (rate 26.3% versus 14.2%; P<0.001), and between-group differences remained after adjustment for other risk factors. 52 However, the age-and sex-adjusted estimated glomerular filtration rate and the prevalence of low estimated glomerular filtration rate was not significantly different between WCH and normotension. In a cross-sectional study of patients with diabetes mellitus, the presence of WCH versus normotension was associated with increased risk of microalbuminuria (OR, 4.9; 95% CI, 1. Damage to the retinal vasculature is also an important consequence of hypertension. In a small study including 20 patients with WCH (classified based on ABPM), the retinal arteriovenous ratio was significantly lower than normotensives (n=50; 0.739±0.127 versus 0.820±0.095; P=0.03), potentially indicating subtle retinal microvascular changes in these patients. 54 However, the results from a longitudinal population survey conducted in a randomly selected Flemish population (n=783) showed that the degree of central retinal arteriolar equivalent narrowing was not significantly different between true normotension and WCH (P≥0.31) over a median 10.3 years of follow-up.
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Stroke
Hypertension increases the risk of stroke, particularly in Japanese/Asian patients. 56, 57 In the Jichi Medical School ABPM study Wave 1, which excluded patients with current or past cardiovascular disease, renal failure or hepatic dysfunction, the incidence of stroke in those with WCH diagnosed using ABPM was similar to that in normotensives, but was 4× higher in patients with sustained hypertension versus normotension. 58 The observational HBPM-based J-HOP (Japan Morning Surge-Home Blood Pressure) cohort study enrolled 4261 treated outpatients. WCH (defined as home BP [the average of morning and evening home values for 14 days] <135/85 mm Hg and clinic BP ≥140/90 mm Hg) was not significantly associated with stroke risk during a median follow-up of 3.9 years. 59 In contrast, the results of a longitudinal Japanese population-based showed that WCH (elevated office BP and normal readings on HBPM and ABPM) was associated with a significantly increased risk of stroke after adjustment for confounding variables (P≤0.006 versus sustained normotension), and this risk was of similar magnitude to that seen in patients with masked or sustained hypertension. 60 Interestingly, when WCH was based on office BP only (ie, no confirmation with out-of-office BP measurements), the risk of stroke was similar to that in normotensive subjects. 60 Although no overall increase in the risk of stroke in patients with WCH was detected in an analysis of individual data from 4 cohort studies (including the Japanese study 58 mentioned above), there was a tendency for the incidence of stroke to increase in the WCH group after the sixth year of follow-up, with stroke rates higher in patients with WCH versus normotension from 9 years' follow-up onwards. 61 Therefore, duration of follow-up might be one factor contributing to the inconsistent association between WCH and stroke risk.
Cardiovascular Disease
Data on the prognostic significance of WCH are inconsistent, with some studies reporting that WCH was independently associated with increased cardiovascular risk, 22, [62] [63] [64] [65] [66] [67] whereas others showed no differences in the risk of cardiovascular events between individuals with WCH and normotensive subjects ( Table 2) . 31, 63, 64, [68] [69] [70] [71] 66 However, the study had several statistical and methodological flaws that decrease the validity of the findings, including the inclusion of a high-risk population referred for ABPM, inappropriate adjustment for antihypertensive drug intake, not accounting for the clustering of end points within centers, and no data on nonfatal end points. 82 In addition, Banegas et al 66 reported higher risk in untreated normotensive subjects as compared to controlled hypertensive subjects, a highly unusual finding. Another study in untreated Italian adults evaluated at an outpatient hypertension clinical showed increased risks of hospitalization for hypertension (OR, 1.927; 95% CI, 1.233-3.013) and heart failure (OR, 3.449; 95% CI, 1.321-9.007) in white-coat hypertensive versus normotensive subjects over a 10-year follow-up, after adjustment for confounding factors including age, BMI, sex, smoking, dyslipidemia, diabetes mellitus, and use of antihypertensive medication. 22 Again though, the study design has some significant limitations, including the retrospective nature of the analysis, the lack of adjudication of events by an independent committee, and a lack of data on metabolic and renal parameters in study participants. In a meta-analysis of data from 8 studies including 20 445 individuals, the risk of cardiovascular disease in patients with untreated WCH was significantly higher than that in normotensive subjects (relative risk, 1.38; 95% CI, 1.15-1.65), and the total mortality risk was also significantly increased (relative risk, 1.20; 95% CI, 1.03-1.40), irrespective of whether WCH was identified using ABPM or HBPM. 72 The authors considered their findings as evidence that WCH is not a benign condition. However, study limitations included a lack of access to individual patient data, restriction of the analysis to studies that reported multivariable-adjusted data, and different out-of-office BP measurement values for defining WCH in the different studies.
There is a more robust body of data suggesting that there is no increased risk of cardiovascular events in low-risk patients with WCH. Ten-year follow-up of a general Japanese Cross-sectional; population cohort 3200 Mean 12 y After adjustment for age and gender, the risk of CV death was increased slightly in WCH (based on ABPM or HBPM), with no significant difference vs normotension; findings were similar after additional adjustment for CVD history, smoking, serum cholesterol, and blood glucose population (n=1332) showed no significant differences between WCH and normotensives in the risk of cardiovascular mortality and stroke morbidity (relative risk, 1.28; 95% CI, 0.76-2.14). 79 In addition, a meta-analysis showed no significant difference between patients with WCH or normotension with respect to fatal and nonfatal cardiovascular events (HR, 1.12; 95% CI, 0.84-1.50), 76 whereas in another meta-analysis, the pooled HR for the incidence of cardiovascular events in WCH versus normotension was 0.96 (95% CI, 0.65-1.42; P=0. 85) . 31 Neither of these analyses used individual patient data or stratified subjects based on use of antihypertensive drug therapy.
The results of an analysis from the IDACO study of community-dwelling adults from 11 countries showed that the rate of cardiovascular disease events was similar in age-matched subjects with untreated WCH (determined based on ABPM) or normotension who were at low risk based on factors included in the ESH/European Society of Cardiology risk score 3 (including male sex, current smoking dyslipidemia, and obesity). 70 In contrast, age-matched high-risk subjects with WCH had a significantly higher rate of cardiovascular events than high-risk normotensives (HR, 2.06; 95% CI, 1.10-3.84; P=0.023). 70 This supports the suggestion that the cardiovascular risk associated with WCH in the absence of other risk factors may be low. 25 The existence of different phenotypes of WCH and corresponding variations in cardiovascular risk has been demonstrated in a large Italian population study. 63 Furthermore, long-term mortality risk in patients with WCH only appears to be increased when office BP is persistently elevated. 73 In summary, there are a number of factors that could contribute to the inconsistencies between results from studies investigating cardiovascular risk and WCH. These include the risk profile of included patients (whether or not subjects have concomitant cardiovascular/metabolic risk factors and the mix of subjects with and without risk factors), the treatment status of study participants (treated, untreated, or a mixture of the two), the criteria used to define WCH, age differences between WCH and normotensive subjects (those with WCH are often markedly older and large differences cannot be completely adjusted for in multivariable models), and the duration of follow-up (WCH may contribute to cardiovascular risk in the long term but not in the short term). Robust studies that take these important factors into account are likely to provide the most reliable estimates of cardiovascular risk in WCH.
Treatment and Monitoring
Few data on the impact of antihypertensive treatment on WCH are currently available to inform patient care. Therapy with lacidipine in the ELSA (European Lacidipine Study on Atherosclerosis) reduced office BP to a similar extent in patients with WCH (based on ABPM) or sustained hypertension, but only consistently lowered out-of-office BP in the group with sustained hypertension. 83 Data from patients with WCH (also diagnosed using ABPM) in the Syst-Eur trial showed that antihypertensive treatment reduced office BP but not ambulatory BP, and there was no evidence for a beneficial effect of therapy on ECG findings or the incidence of stroke. 84 In addition, reductions in BP and cardiovascular morbidity/mortality during treatment with antihypertensives were of a smaller magnitude in individuals with WCH compared to those with sustained hypertension. 84 There are currently no randomized controlled trials showing a beneficial effect of antihypertensive drug therapy on cardiovascular outcomes in individuals with WCH. However, treatment of very elderly patients with hypertension (indapamide±perindopril) in the HYVET (Hypertension in the Very Elderly) study was associated with important reductions in cardiovascular events and all-cause mortality; 50% of patients enrolled in that study met the office and ABPM BP criteria for WCH. 85 Although this could suggest that there may be some benefits of antihypertensive therapy in the WCH population, the findings came from a post hoc analysis and needed to be interpreted and applied with caution.
It has been suggested that antihypertensive treatment should be reserved for patients with elevated out-of-office BP (using ABPM or HBPM) and patients who are at high cardiovascular risk or who demonstrate hypertension-related target organ damage. 86 Given the focus of latest international guidelines on cardiovascular risk in determining management strategies for hypertension, 2,3 it seems reasonable to suggest that management of patients with WCH should include careful assessment of cardiovascular risk, including investigation of potential subclinical target organ damage. High-risk patients could be defined as those with an estimated 10-year atherosclerotic cardiovascular disease risk of ≥10%, as defined in the ACC/AHA 2017 guidelines. 2 Relevant arguments against initiating antihypertensive therapy in the setting of WCH include the fact that office BP is a less reliable predictor of cardiovascular outcomes than out-of-office BP, [87] [88] [89] [90] [91] [92] [93] that WCH is more common in patients with mild hypertension who are likely to be at lower cardiovascular risk, the potential for hypotensive adverse effects of therapy in patients with normal out-of-office BP (especially in the elderly), 94 and no apparent increase in cardiovascular events in low-risk patients with WCH. 32, 70 However, the risk of progression to sustained hypertension in the presence of other cardiovascular or metabolic risk factors, suggests that regular monitoring of WCH could be beneficial, even in the absence of ongoing pharmacological therapy.
The latest US guidelines do not recommend any treatment for individuals with WCH based on the fact that they have normal out-of-office BP readings. 2 Thus, after detection and diagnosis of WCH, lifestyle modifications are suggested, with annual ABPM or HBPM to facilitate detection of progression to sustained hypertension. 2 Similar recommendations are made in the Taiwanese guidelines. 5 European guidelines recommend lifestyle modification for patients with uncomplicated WCH. In addition to lifestyle modifications, antihypertensive treatment should be considered for patients with WCH who have evidence of hypertension-mediated organ damage or in whom cardiovascular risk is high or very high; for all other patients with WCH, routine drug treatment is not indicated. 3 Close follow-up of all patients using out-of-office BP monitoring is recommended. In contrast, the National Institute for Health and Care Excellence hypertension treatment guidelines do not include any recommendation for the treatment of WCH, and also do not see a need for ongoing follow-up/monitoring in these patients. 95 
Masked Hypertension
In untreated individuals, the presence of normal BP on clinic or office BP readings and elevated out-of-office BP is referred to as MH; for treated patients, the corresponding term is masked uncontrolled hypertension. WCH and subtypes of MH could be considered as a manifestation of increased BP variability triggered by a variety of pressor factors (Figure 2) . Therefore, MH could be characterized by elevated morning, daytime, and nighttime BP (Figure 2) . Overall, MH is of clinical significance given its association with an increased risk of cardiovascular disease and target organ damage. In this article,
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the term MH will be used to refer to untreated patients unless otherwise specified.
Detection and Diagnosis
Twenty-four-hour ABPM is the gold standard for diagnosing hypertension and assessment of 24-hour BP, including both daytime and nighttime values, and is important to facilitate the diagnosis of MH. 96 Most international guidelines recommend the use of any out-of-office BP monitoring technique, such as ABPM or HBPM, to screen for MH.
2-6,45,95,97-99 ABPM may be preferred for the reliable detection of MH. A study conducted in China showed that HBPM missed the diagnosis of MH in >25% of patients. 100 Although specificity is high, home BP has low sensitivity for the diagnosis of MH, and could therefore be seen as a complementary strategy to ABPM rather than an alternative. 13 In a study comparing the 2 out-of-office BP measurement methods, there was disagreement in the diagnosis of MH in 23% of subjects based on SBP and in 30% of subjects based on diastolic BP, but this was reduced to 9% and 5%, respectively, when a 5-mm Hg uncertainty range was applied to the diagnostic threshold. 101 The authors concluded that both methods were appropriate for the diagnosis of MH, although it is important to be aware that the 2 approaches may not always provide consistent diagnoses. In contrast, a systematic review by the US Preventive Services Task Force described ABPM as the first-choice diagnostic method for detecting MH and WCH. 102 Advantages of ABPM over HBPM include the ability to identify patients with normal BP during the day but masked nocturnal hypertension, and the fact that readings are taken during normal daily activities rather than at rest. 96 One approach could be that if MH is diagnosed based on HBPM, this could be confirmed by ABPM before consideration and initiation of antihypertensive therapy. 103 It is not practical to refer all patients with high-normal office BP for out-of-office BP monitoring, and making outof-office BP screening decisions based on clinic BP alone appears suboptimal. 104 The presence of target organ damage or other cardiovascular risk factors in patients with normal clinic BP is a good criteria by which to target patients who would benefit from ABPM and HBPM to screen for the presence of MH 105, 106 given that approximately one-third of individuals with normal BP in the presence of target organ damage or cardiovascular disease history have MH. 107 Another approach using a clinic BP index to identify individuals for whom MH screening might be useful was investigated in the US study. The index developed in a validation cohort was clinic SBP+(1.3×clinic diastolic BP). Using index values of ≥190 and ≥217 mm Hg had sensitivity of 98.5% and 71.5% for detecting MH (compared with 82.5% for MH screening based on prehypertension status). 108 Using a clinic BP index with a slightly lower sensitivity could provide the best balance between detecting MH and limiting the number of individuals screened with ABPM to realistic and achievable levels. 108 Another potential approach to targeting additional screening is to look at the characteristics of repeated BP measures over one clinic visit, which has been shown to predict differences between clinic and out-of-office BP values. 12 Use of repeated measures usually decreases the white-coat effect for office BP meaning that the difference between office BP and outof-office BP becomes smaller. It is therefore possible that MH may be more likely when high-normal office BP persists at the end of repeated measurements. Alternatively, individuals from specific populations or those with certain characteristics associated with a higher prevalence of MH, including males, older individuals, smokers, and those with a high BMI, diabetes mellitus, or hypercholesterolemia, 107 could be targeted for further assessment when office BP is normal. The latest US guidelines suggest that out-of-office screening for MH is reasonable in adults with untreated office BP values that are consistently between 120/75 and 129/79 mm Hg. 
Prevalence, Predictors, and Epidemiology
Reported prevalence rates for MH vary between studies, probably because of differences in the populations studied, how MH is defined, and the assessment tools used to confirm the diagnosis. Analysis of data from 10 community-dwelling cohorts on 3 continents (all participants in IDACO) reported a MH prevalence of 13.4% overall and 19.1% among subjects who were normotensive on conventional measurement (MH was diagnosed as office BP <140/90 mm Hg and ambulatory BP ≥130/80 mm Hg). 25 Prevalence was similar (16.4%) in the African-PREDICT study (African Prospective Study for the Early Detection and Identification of Cardiovascular Disease and Hypertension; a cross-sectional analysis of adults aged 20-30 years) 109 and in a population of untreated Chinese outpatients referred for ABPM (20.0%), 100 whereas lower rates were reported in the IDHOCO study (International Database of Home Blood Pressure in Relation to Cardiovascular Outcome; 8.1% overall and 11.9% in individuals who were normotensive on conventional measurement) 67 and in an untreated Italian adult population (6.7%). 22 In a systematic review and meta-analysis of prevalence data for African populations (pooled n=7789), the prevalence of MH was 11% (95% CI, 4.7-19.3). 23 Similar rates were reported in a Canadian population, with MH documented in 11.1% of women and 17.7% of men. Estimated prevalence of MH in US adults over the period 2005 to 2010 was 12.3% (95% CI, 10%-14.5%), equating to 17.1 million individuals 
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aged ≥21 years who have normal office BP but out-of-office hypertension. 110 A number of factors are associated with a higher prevalence of MH, including increasing age, higher BMI, alcohol intake, family history of cardiovascular disease, presence of prehypertension, diabetes mellitus or chronic kidney disease, greater BP variability, smoking, and excessive alcohol intake. [110] [111] [112] [113] [114] [115] [116] [117] [118] [119] In addition, nocturnal hypertension is common in conditions such as the metabolic syndrome, chronic kidney disease, diabetes mellitus, obstructive sleep apnea, or short sleep time, meaning that MH is more common in these groups. 117, [120] [121] [122] [123] Geographic and ethnic variations in the prevalence of MH have been reported, 19, 110, 124 including higher rates in some specific populations, such as African-Americans. 125, 126 Similar to WCH, the definition and diagnosis of MH are dependent on the cutoff values used to define the condition (Table 1 ). When applied to data from the Spanish ABPM registry, prevalence rates for MH were 14.3% using the ESH criteria of mean daytime BP ≥135/85 mm Hg and 29.7% using the ACC/AHA criteria of mean daytime BP ≥130/80 mm Hg. 127 The highest prevalence rate (60.2%) occurred using the new ACC/AHA criteria with mean daytime BP ≥130/80 mm Hg, mean 24-hour BP ≥125/75 mm Hg, or mean nighttime BP ≥110/60 mm Hg. 127 Overall, prevalence rates for MH were approximately doubled when the ACC/AHA versus European Society of Cardiology criteria were used. 127 The prevalence of MH also varies based on the measures used for out-of-office BP. Based on these data, the prevalence of MH could be underestimated if only 24-hour or daytime BP was used to define the condition. 25, 128 Therefore, work is needed to clearly define and standardize diagnostic criteria. 129 MH based on normal office BP and elevated BP during ABPM has been shown to have quite good reproducibility-persisting in 72% of subjects on repeat testing.
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Effect on Prognosis
Available data suggest that the presence of MH is associated with elevated risk of target organ damage, cardiovascular events, and mortality, approaching the risk observed in patients with sustained hypertension.
Risk of Developing Sustained Hypertension
Individuals with MH are at increased risk of progressing to sustained hypertension compared with normotensives (OR, 1.78, adjusted for sex and age; P<0.0001 based on 10-year follow-up data from an Italian longitudinal study). 33 After 3 years of follow-up in a Canadian population-based study, more than half of all participants who had MH at baseline had developed sustained hypertension. Rates for the proportion of patients with MH at baseline who had MH or sustained hypertension at 3 years were 62% for men and 66% for women, and 37% of those with MH at baseline had progressed to sustained hypertension at the 5-year follow-up. 111 Finnish data showed that 73% of MH subjects developed sustained hypertension over a longer follow-up duration (11 years).
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Target Organ Damage
The increased risk of target organ damage in the presence of MH was first recognized in 1999, when it was reported that patients with MH had a higher LV mass and more carotid atherosclerosis than subjects with true normotension. 131 Since then, a number of studies have documented associations between measures of LV damage, including increased LV mass index, and MH. These adverse outcomes may to be of a similar, or potentially even greater, magnitude than those associated with sustained hypertension. 131, 132 Conversely, data from an Italian population-based study reported that the prevalence of LV hypertrophy in individuals with MH was 14%, intermediate between that in patients with sustained hypertension (16%) and those with normal BP (4%). 21 In the African-PREDICT study, subjects with MH were at higher risk of having an increased LV mass index (OR, 1.67; P=0.031 versus normotensives). 109 On multivariable-adjusted linear regression analysis, LV mass index was positively and independently correlated with MH (P=0.046), although there was no independent association of echocardiographic measures of LV function with MH. 109 Another important marker of target organ damage is atherosclerosis. MH was significantly associated with increased carotid IMT, an indicator of early carotid atherosclerosis, in a clinical trial 133 and when trial results were combined in a meta-analysis. 134 Measured using ultrasonography of the carotid artery, higher IMT was reported in patients with MH compared to those with normal BP (0.76±0.20 versus 0.64±0.14 mm; P<0.05). 135 In a Japanese study of patients with at least one cardiovascular risk factor, MH defined by HBPM (office BP <140/90 mm Hg and home BP ≥135 and 85 mm Hg) was significantly associated with impaired flow-mediated vasodilatation in the brachial artery. 136 The presence of albuminuria indicates renal function impairment, is associated with hypertension, 3, 6 and has been linked with both cardiovascular disease and mortality. 137 In a general population from Japan (adults aged ≥40 years), MH was significantly associated with the presence of albuminuria (rate 26.4% versus 14.1% for normotensives [P<0.001] and 43.3% for sustained hypertension [also P<0.001 versus normotensives]) after adjustment for other risk factors. 52 Geometric mean values for the urinary albumin-to-creatinine ratio (UACR) were also significantly higher in patients with MH versus normotension (P<0.001), but sex-and age-adjusted estimated glomerular filtration rate did not differ between the 2 groups. 52 Furthermore, over a follow-up period of 5.9 to 12.2 (median 8.0) years, MH was not significantly associated with rapid kidney function decline in African-Americans (n=676) in a multivariable-adjusted analysis from the Jackson Heart Study (OR, 1.07; 95% CI, 1.67-1.70). 138 In addition, when a propensity score was used to simultaneously adjust for sex, age, education, estimated glomerular filtration rate, UACR, BMI, diabetes mellitus, total cholesterol, high-sensitivity C-reactive protein, physical activity, current cigarette smoking, alcohol use, and self-reported use of antihypertensive medication, the relation between the risk of chronic kidney disease and MH was not statistically significant (OR, 1.62; 95% CI, 0.87-3.00). 138 In prospective cohort study conducted in Japan, the risk of progression to macroalbuminuria in patients with type-2 diabetes mellitus was increased to a greater extent versus normotension in the presence of MH (adjusted OR, 8 Abnormalities in the retinal vasculature predict the development of hypertension and increased cardiovascular risk in patients with hypertension. 140, 141 The retinal arteriovenous ratio in subjects with MH has been shown to be significantly lower than that in normotensives (0.716±0.123 versus 0.820±0.095; P<0.001), potentially indicating subtle retinal microvascular changes in these patients. 54 However, the degree of central retinal arteriolar equivalent narrowing was not significantly different between true normotension and MH (P≥0.31) over a median 10.3 years of follow-up in a randomly selected Flemish population (n=783). 55 
Stroke
In the Ohasama study, both stroke morbidity and cardiovascular mortality were increased to a similar extent in patients with MH and those with sustained hypertension. 79 The association between MH and stroke in that study was not dependent on the out-of-office BP monitoring tool used to diagnose MH. The increase in stroke risk in MH versus normotension amounted to an HR of 2.05 (95% CI, 1.23-3.41) when MH was detected on ABPM and HBPM, 1.93 (95% CI, 1.15-3.24) with detection on ABPM but not HBPM, and 2.26 (95% CI, 1.33-3.89) when MH was detected on HBPM but not ABPM. 60 In the Japanese general practice population, MH diagnosed using HBPM was associated with an increased risk of stroke. In the J-HOP study, the MH group had a higher risk of stroke compared with the controlled BP group (HR, 2.77; 95% CI, 1.20-6.37), independent of traditional cardiovascular risk factors, the UACR and circulating B-type natriuretic peptide levels. In contrast, MH did not increase coronary heart disease risk, although the follow-up duration of 2.4 to 4.6 (median 3.9) years may have been insufficient to reliably determine this end point.
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Cardiovascular Disease
There is sound evidence supporting an association between the increased risk for cardiovascular events and MH (Table 3) .
Fifteen years ago a Swedish longitudinal study in a population of 578 untreated 70-year-old men reported that MH (normal office BP and elevated BP on ABPM) was a significant independent predictor of cardiovascular morbidity (HR, 2.77; 95% CI, 1.15-6.68) after adjustment for cholesterol levels, smoking status, and diabetes mellitus. 143 Increased cardiovascular risk associated with MH based on ABPM has been confirmed in a number of other studies, 22, 62, [77] [78] [79] and appears to be almost equivalent to that in patients with sustained hypertension. 31, 69, 76, 143, 144 Data from a large Italian cohort of untreated adults followed for 10 years showed that MH was associated with an increased risk of myocardial infarction (OR, 5.062; 95% CI, 2.218-11.550), and hospitalization for hypertension (OR, 2.553; 95% CI, 1.446-4.508) or heart failure (OR, 4.214; 95% CI, 1.449-12.249). 22 All associations remained statistically significant after adjustment for confounding factors including sex, age, BMI, smoking, dyslipidemia, diabetes mellitus, and presence of antihypertensive therapies. 22 Increased cardiovascular risk has also been documented for MH diagnosed using HBPM. 62, 80 In one study, the adjusted HR for cardiovascular events was 2.06 (95% CI, 1.22-3.47) in patients with MH versus normotensives. 80 Significantly increased risk for MH (diagnosed with HBPM) compared with normotension over a mean 8.3 years' follow-up was also documented in the IDHOCO study (HR for cardiovascular events, 1.55; 95% CI, 1.12-2.14; P<0.01). 67 A number of meta-analyses (including studies using either ABPM or HBPM for MH diagnosis) provide robust data to support the association between increased cardiovascular risk and MH. 76, 144 In the latest meta-analysis, which included data from 14 729 participants from 9 studies followed over a mean of 9.5 years, rates of cardiovascular events (12.3%), and all-cause mortality (15.8%) in patients with MH were significantly higher compared with both normotensives (OR, 2.91; 95% CI, 2.54-3.33; and OR, 2.65; 95% CI, 2.18-3.23, respectively) and subjects with WCH (OR, 1.38; 95% CI, 1.04-1.83; and OR, 1.71; 95% CI, 1.34-2.19, respectively). In this analysis, the risk of cardiovascular events in MH was actually lower than that in patients with sustained hypertension (OR, 0.61; 95% CI, 0.42-0.89), but the all-cause mortality risk was similar in the 2 groups (OR, 1.00; 95% CI, 0.44-2.26). 103 In an overview of literature available at the time (2010), Angeli et al 145 reported that the risk of major cardiovascular disease was higher in patients with MH compared with normotensive subjects, regardless of how MH was defined (HR, 2.13; 95% CI, 1.35-3.35; P=0.001 for self-measured BP and HR, 2.00; 95% CI, 1.54-2.60; P<0.001 for 24-hour ambulatory BP).
Treatment
The well-documented increase in cardiovascular risk associated with MH provides a good rationale for its treatment. In addition, BP determined using out-of-office measurement provides better cardiovascular risk stratification than office BP. 66, 93, 146, 147 Nevertheless, there are limited data on the best way to treat MH, and there have not been any prospective clinical trials to date looking at the effect of treating MH on the risk of cardiovascular events and mortality. However, retrospective analysis of data from the JMS-1 (Japan Morning Surge-1) and J-TOP (Japan Morning Surge-Target Organ Protection) studies showed that treatment of MH (defined as clinic BP <140/90 mm Hg and home morning SBP ≥135/85 mm Hg) with intensive antihypertensive therapy targeting the morning home BP was associated with significant reductions from baseline in the UACR, pulse wave velocity, and LV mass index over 6 months, all of which indicate decreased target organ damage. 148 The Jackson Heart Health study suggested that lifestyle modifications may be beneficial in MH with a lower prevalence of MH seen in individuals with better cardiovascular health. 149 However, optimal treatment of MH often requires the use of combination antihypertensive therapy. 150 During pharmacological therapy of MH, regular monitoring with ABPM or HBPM is required to ensure that masked uncontrolled hypertension does not occur, and that good BP control is achieved and maintained. Perhaps because of the lack of published evidence, there is little guidance on management strategies for MH. The only major guidelines to specifically address this issue are those from the ESH/European Society of Cardiology. 3 Given the presence of cardiovascular risk similar to that in patients with sustained hypertension, the European Society of Cardiology/ ESH guidelines state that both lifestyle measures and antihypertensive drug therapy should be considered, although the lack of evidence is acknowledged (Level of Evidence C). 3 In addition, it is suggested that metabolic and organ damage risk factors need to be considered because of their increased prevalence in MH and that ABPM and HBPM should be used for long-term monitoring. 
Conclusions
Both WCH and MH are important, well-described, and relatively common hypertension subtypes that are identified using out-of-office BP monitoring techniques, although BP cutoff values now vary between major international guidelines. It is well-recognized that BP measured outside the clinic setting using ABPM and HBPM provides more accurate information about cardiovascular risk in patients with hypertension than office BP, highlighting the importance of determining out-ofoffice BP. However, there remains some uncertainty about the optimum out-of-office tool (ABPM or HBPM) to detect MH.
Although there is no clear consensus about the level of cardiovascular risk associated with WCH, the latest evidence suggests that this is only increased in the presence of other cardiovascular and metabolic risk factors, an entity that could be described as WCH syndrome (Figure 3) . 51 Therefore, accurate risk assessment in WCH requires the definition and identification of different phenotypes and consideration of concomitant risk factors. In contrast, there is good evidence to suggest that MH is not a benign condition and is associated with significantly increased risk of target organ damage, cardiovascular disease, and death. Individuals with normal office BP and coexisting target organ damage, cardiovascular disease, or cardiovascular disease history are likely to be the group who would benefit most from out-of-office BP measurement to screen for MH.
The role of antihypertensive therapy in both WCH and MH has not been well-studied to date. Additional research is needed to clarify the role of pharmacological treatment in patients with WCH, and to identify whether a subset of individuals with WCH might benefit from antihypertensive therapy. The consistently increased cardiovascular risk documented in patients with MH suggests that, despite a current lack of evidence, treating MH would be warranted. However, there is an important need for outcome studies to provide robust evidence about the role of antihypertensive therapy in patients with MH, particularly with respect to cardiovascular risk management. It remains to be determined whether antihypertensive therapy for MH can reduce cardiovascular risk to the same extent as seen in patients with sustained hypertension. Data from randomized clinical trials 
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March 29, 2019 in this area are urgently needed to inform major guidelines, which need to recognize the importance of MH and provide recommendations about the optimal diagnostic, treatment, and monitoring strategies (Table 4 ).
